𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: Implications for tumor angiogenesis

✍ Scribed by Christopher G. Kevil; Arrigo De Benedetti; D. Keith Payne; Laura L. Coe; F. Stephen Laroux; J. Steven Alexander


Publisher
John Wiley and Sons
Year
1996
Tongue
French
Weight
832 KB
Volume
65
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


Studies aimed at elucidating the function of the protein synthesis factor eukaryotic initiation factor 4E (elF

) have demonstrated that overexpression of this protein results in marked cell phenotypic and proliferative changes, including neoplastic transformation of cells. These data suggest that elF-4E may somehow participate in the development and progression of tumors in vivo. In order to determine how elF-4E exerts its transforming effects, we examined vascular permeability factor (VPF) levels in cells transfected with an elF-4E vector. Cells overexpressing elF-4E showed an increase in intracellular, and an average 130-fold increase in secreted VPF protein levels (CHO 0.13 f 0.12 ng/ml; CHO-4E 20.5 2 12.5 ng/ml) over control cells. HUVEC growth induction revealed these VPF levels to be biologically active. Northern analysis revealed no difference in VPF transcript between the 2 cell lines. Polysome analysis showed that the VPF message in elf-4E-transfected cells was associated with the heavy polysomal regions, whereas the VPF message was associated with light polysomes in control cells. These data strongly suggest that enhanced VPF expression is achieved through translational regulation rather than transcriptional regulation in cells overexpressing elF-4E. This indicates that elf-4E-induced VPF expression may be an important factor in some forms of tumor angiogenesir and development.


📜 SIMILAR VOLUMES


Proto oncogene/eukaryotic translation in
✍ Robbie D. Buechler; Dennis M. Peffley 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 334 KB

## Abstract The rate‐limiting enzyme for mevalonate synthesis in mammalian cells is 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA) reductase. Products of mevalonate synthesis are required for cell cycle progression as well as cell growth and survival. In tumor cells, HMG‐CoA reductase is generally